Updated on 2026/04/15

写真a

 
HORI Kazumi
 
Organization
Nagoya University Hospital Respiratory Medicine Assistant Professor
Graduate School
Graduate School of Medicine
Title
Assistant Professor

Degree 1

  1. 学士(医学) ( 2008.3   福井大学 ) 

Professional Memberships 9

  1. 日本内科学会

  2. 日本呼吸器学会

  3. 日本癌学会

  4. 日本呼吸器内視鏡学会

  5. 日本臨床腫瘍学会

  6. 日本がん治療認定医機構

  7. 日本肺癌学会

  8. 日本結核・非結核性抗酸菌症学会

  9. American Association for Cancer Research

▼display all

 

Papers 3

  1. PBK Expression Promotes the Aggressive Phenotypes of Mesothelioma Reviewed

    Hori, K; Tanaka, I; Sato, T; Sato, M; Kodama, Y; Itoigawa, H; Abe, Y; Kato, T; Taguchi, A; Sato, M; Sekido, Y; Chen-Yoshikawa, TF; Ishii, M

    CANCER SCIENCE     2025.6

     More details

    Authorship:Lead author   Language:English  

    DOI: 10.1111/cas.70124

    Web of Science

    PubMed

  2. Favorable clinical impact of histological subtype with non-small cell carcinoma-not otherwise specified in patients with non-small cell lung cancer receiving immune checkpoint inhibitors Reviewed Open Access

    Tatsuya Hirano, Ichidai Tanaka, Masahiro Morise, Junji Koyama, Takahiko Hashimoto,Kazumi Hori,Reiko Matsuzawa, Sho Hori, Kennosuke Karube, Takayasu Ito, Koji Sakamoto, Yuichiro Shindo, Mitsuo Sato, Toshihiko Yokoyama, Tomoki Kimura, Yasuhiro Kondoh, Makoto Ishii

    Respiratory Investigation     2026.3

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    DOI: 10.1016/j.resinv.2026.101383.

    Open Access

  3. Femoral bone metastasis is a poor prognostic factor in EGFR-TKIs-treated patients with <i>EGFR</i>-mutated non-small-cell lung cancer: a retrospective, multicenter cohort study Reviewed

    Tanaka, I; Hori, K; Koyama, J; Gen, S; Morise, M; Kodama, Y; Matsui, A; Miyazawa, A; Hase, T; Hibino, Y; Yokoyama, T; Kimura, T; Yoshida, N; Sato, M; Ishii, M

    THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY   Vol. 16   page: 17588359241303090   2024

     More details

    Language:English   Publisher:Therapeutic Advances in Medical Oncology  

    Background: Epidermal growth factor receptor (EGFR)-mutant non-small-cell lung cancers (NSCLCs) have higher frequencies of bone metastases than those of wild type; however, the metastatic pattern and influence on clinical outcome remain unclear. Objectives: To analyze the association between bone metastatic sites and the clinical efficacy of the first-, second-, and third-generation EGFR-tyrosine kinase inhibitors (TKI), in these patients. Design: Retrospective multicenter cohort study. Methods: The clinical data of patients with advanced-NSCLC harboring EGFR mutation, who were treated by EGFR-TKIs as first-line treatment at five medical institutions (N = 411), were retrospectively assessed for bone metastatic sites, overall survival (OS), and progression-free survival (PFS). Results: Bone metastases were found in 41.1% of the patients at diagnosis, including 13.1%, 8.0%, and 20.0 for single, double, and multiple lesions (⩾3), respectively. The vertebra (76.3%) and pelvis (60.9%) were the most frequent metastatic sites. Femoral-, sternum-, and scapula-metastases were remarkably increased in the patients with multiple-bone metastases. In the EGFR-mutant NSCLC patient treated with osimertinib, both the OS and the PFS of the patients with femoral bone metastasis were significantly shorter than those of the patients without femoral bone metastasis (OS: not reached vs 12.1 months, p < 0.0001; and PFS: 17.2 vs 9.3 months, p < 0.0018). Furthermore, a multivariable Cox regression analysis, including several poor prognostic factors, such as L858R mutation and liver metastasis, demonstrated that femoral bone metastasis was a statistically independent predictor of OS. Conclusion: Femoral bone metastasis is associated with poor survival of EGFR-mutant NSCLC patients who were treated with EGFR-TKIs, including osimertinib, and is an independent prognostic factor of OS.

    DOI: 10.1177/17588359241303090

    Web of Science

    Scopus

    PubMed

Presentations 15

  1. PBK expression promotes the aggressive phenotypes of mesothelioma. International conference

    Kazumi Hori, Ichidai Tanaka, Tatsuhiro Sato, Mika Sato, Yuta Kodama, Hideyuki Itoigawa, Yuichi Abe, Taketo Kato, Ayumu Taguchi, Mitsuo Sato, Yoshitaka Sekido, Toyofumi Fengshi Chen-Yoshikawa, Makoto Ishii

    AACR Annual Meeting 2025  2025.4.28  American Association for Cancer Research

     More details

    Event date: 2025.4

    Language:English   Presentation type:Poster presentation  

    Venue:Chicago   Country:United States  

  2. PDZ-binding kinase promotes cell migration and could be a promising therapeutic target in mesothelioma

    Kazumi Hori, Ichidai Tanaka, Tatsuhiro Sato, Mika Sato, Yuta Kodama, Hideyuki Itoigawa, Yuichi Abe, Taketo Kato, Ayumu Taguchi, Mitsuo Sato, Yoshitaka Sekido, Toyofumi Yoshikawa, Makoto Ishii

    2025.9.25 

     More details

    Event date: 2025.9

    Language:English   Presentation type:Oral presentation (general)  

    Country:Japan  

  3. 悪性胸膜中皮腫においてPDZ binding kinaseは新規治療標的となりうる

    堀 和美、田中 一大、佐藤 美佳、糸魚川 英之、加藤 毅人、佐藤 龍洋、佐藤 光夫、関戸 好孝、芳川 豊史、石井 誠

    第65回 日本呼吸器学会学術講演会  2025.4.12  日本呼吸器学会

     More details

    Event date: 2025.4

    Language:Japanese   Presentation type:Poster presentation  

    Venue:東京国際フォーラム   Country:Japan  

  4. KEAP1-NRF2変異NSCLCにおける共変異シグネチャと臨床転帰:C-CATデータベースを用いた全国規模コホート解析

    田中 一大、大矢 由子, 徳永 康太, 野口 陽一郎, 神山 潤二, 松澤 令子, 堀 和美, 佐藤 光夫, 石井 誠

    第23回日本臨床腫瘍学会学術集会  日本臨床腫瘍学会

     More details

    Event date: 2026.3

    Language:Japanese   Presentation type:Poster presentation  

    Venue:横浜   Country:Japan  

  5. C-CATデータベースを用いた非小細胞肺癌におけるKRAS変異の遺伝子プロファイリング

    後藤 希、野口 陽一朗, 神山 潤二, 松澤 令子, 堀 和美, 田中 一大, 石井 誠

    第23回 日本臨床腫瘍学会学術集会  日本臨床腫瘍学会

     More details

    Event date: 2026.3

    Language:Japanese   Presentation type:Poster presentation  

    Venue:横浜   Country:Japan  

  6. Clinical outcomes of osimertinib for advanced EGFR-mutated LUAD based on the 9th TNM classification: a multicenter study

    Ichidai Tanaka, Mika Sato, Kazumi Hori, Junji Koyama, Yuta Kodama, Akira Matsui, Ayako Miyazawa, Shoko Miyamatsu, Shuichi Asano, Yoshitaka Hibino, Masahiro Morise, Toshihiko Yokoyama, Tomoki Kimura, Norio Yoshida, Mitsuo Sato, Makoto Ishii

     More details

    Event date: 2025.9

    Language:English   Presentation type:Poster presentation  

    Country:Japan  

  7. Real-world clinical outcomes of osimertinib in patients with recurrent EGFR-mutated lung adenocarcinoma: a multicenter study. International conference

    Ichidai Tanaka, Mika Sato, Kazumi Hori, Junji Koyama, Yuta Kodama, Akira Matsui, Ayako Miyazawa, Shoko Miyamatsu, Shuichi Asano, Yoshitaka Hibino, Masahiro Morise, Toshihiko Yokoyama, Tomoki Kimura, Norio Yoshida, Mitsuo Sato, Makoto Ishii

    WCLC 2025  International Association for the Study of Lung Cancer

     More details

    Event date: 2025.9

    Language:English   Presentation type:Poster presentation  

    Country:Spain  

  8. 治療抵抗性の気管支カルチノイドに対してルテチウムオキソドトレオチドを投与し、病変を制御できた一例

    柴田 佑子、中瀬  敦、速井 俊作、神山 潤二、伊藤 貴康、堀  和美、安藤  啓、田中 一大、阪本 考司、長谷 哲成、進藤有一郎、森瀬 昌宏、石井  誠

    第127回 日本呼吸器学会東海地方会  日本呼吸器学会 東海支部

     More details

    Event date: 2025.5

    Language:Japanese   Presentation type:Oral presentation (general)  

    Venue:名古屋   Country:Japan  

  9. ロイス・ディーツ症候群を背景とした反復性喀血に対し て、在宅トラネキサム酸吸入療法が奏効した一例

    鈴木あかり、神山 潤二、中瀬  敦、速井 俊策、伊藤 貴康、堀  和美、安藤  啓、田中 一大、阪本 考司、長谷 哲成、進藤有一郎、森瀬 昌宏、石井  誠

    第127回日本呼吸器学会東海地方会  日本呼吸器学会 東海支部

     More details

    Event date: 2025.5

    Language:Japanese   Presentation type:Oral presentation (general)  

    Venue:名古屋   Country:Japan  

  10. EGFR遺伝子変異陽性肺腺癌の術後再発症例に対するOsimertinibの治療効果の検討

    佐藤美佳、田中一大、堀 和美、神山潤二、長谷哲成、森瀬昌宏、佐藤光夫、石井誠

    第65回 日本呼吸器学会学術講演会  2025.4  日本呼吸器学会

     More details

    Event date: 2025.4

    Language:Japanese   Presentation type:Poster presentation  

    Venue:東京国際フォーラム   Country:Japan  

  11. Prognostic impact of bone metastases in osimertinib-treated patients with EGFR-mutated NSCLC

    Ichidai Tanaka, Kazumi Hori, Junji Koyama, Soei Gen, Masahiro Morise, Yuta Kodama, Akira Matsui, Ayako Miyazawa, Tetsunari Hase, Yoshitaka Hibino, Toshihiko Yokoyama, Tomoki Kimura, Norio Yoshida, Mitsuo Sato, Makoto Ishii

    2025.3.7 

     More details

    Event date: 2025.3

    Language:English   Presentation type:Poster presentation  

  12. ペムブロリズマブの増量・投与間隔延長時に免疫関連大腸炎を発症した肺扁平上皮癌の一例

    後藤希、神山潤二、堀和美、田中一大、石井誠、澤田つな騎

    第126回日本肺癌学会中部支部学術集会  2025.2.8 

     More details

    Event date: 2025.2

    Language:Japanese   Presentation type:Oral presentation (general)  

    Venue:名古屋   Country:Japan  

  13. 術後再発したEGFR遺伝子変異陽性肺腺癌に対するOsimertinibの治療効果の解析

    佐藤美佳、田中一大、堀和美、神山潤二、小玉勇太、松井彰、宮沢亜矢子、宮松晶子、浅野周一、長谷哲成、日比野佳孝、森瀬昌宏、横山俊彦、木村智樹、吉田憲生、佐藤光夫、石井誠

    第65回日本肺癌学会学術集会  2024.11.2  日本肺癌学会

     More details

    Event date: 2024.10 - 2024.11

    Language:Japanese   Presentation type:Oral presentation (general)  

    Venue:パシフィコ横浜  

  14. Prognostic impact of bone metastases in osimertinib-treated patients with EGFR-mutated NSCLC

    Ichidai Tanaka, Kazumi Hori, Junji Koyama, Soei Gen, Masahiro Morise, Yuta Kodama, Akira Matsui, Ayako Miyazawa, Tetsunari Hase, Yoshitaka Hibino, Toshihiko Yokoyama, Tomoki Kimura, Norio Yoshida, Mitsuo Sato, Makoto Ishii

    2024.9.19 

     More details

    Event date: 2024.9

    Presentation type:Poster presentation  

  15. Femoral bone metastasis is a poor prognostic factor in Osimertinib-treated patients with EGFR-mutated NSCLC

    Ichidai Tanaka, Soei Gen, Kazumi Hori, Masahiro Morise, Junji Koyama, Yuta Kodama, Akira Matsui, Ayako Miyazawa, Tetsunari Hase, Yoshitaka Hibino, Toshihiko Yokoyama, Tomoki Kimura, Norio Yoshida, Mitsuo Sato, Makoto Ishii

    2024.4.6 

     More details

    Event date: 2024.4

    Presentation type:Poster presentation  

▼display all

Research Project for Joint Research, Competitive Funding, etc. 2

  1. オキシトシン受容体の下流シグナルを標的とした悪性中皮腫に対する新規治療の開発

    Grant number:24ck0106972h0001  2024

    国立研究開発法人日本医療研究開発機構  革新的がん医療実用化研究事業 

      More details

    Authorship:Principal investigator  Grant type:Competitive

    Grant amount:\39000000 ( Direct Cost: \30000000 、 Indirect Cost:\9000000 )

  2. 中皮腫における移動能を促進する新規治療標的の探索

    Grant number:2026M03  2026.3 - 2027.3

    一般社団法人中皮腫治療推進基金  中皮腫治療研究助成金 

    田中一大、佐藤龍洋

      More details

    Authorship:Principal investigator  Grant type:Other

    Grant amount:\100

KAKENHI (Grants-in-Aid for Scientific Research) 2

  1. 胸膜中皮腫の腫瘍微小環境を標的とした新規治療法の開発

    2026.4 - 2029.3

    科学研究費助成事業  基盤研究(C)

    田中一大、佐藤龍洋

      More details

    Authorship:Principal investigator  Grant type:Competitive

    Grant amount:\3500000

  2. ピリミジン塩基合成経路を標的としたLKB1不活化肺癌に対する新規治療法の開発

    Grant number:23K27611  2023.4 - 2026.3

    科学研究費助成事業  基盤研究(B)

    田中 一大, 関戸 好孝, 田口 歩, 佐藤 光夫, 佐藤 龍洋, 堀 和美

      More details

    Authorship:Coinvestigator(s) 

    非小細胞肺癌の約20%は、腫瘍抑制遺伝子であるLiver kinaseB1(LKB1)の不活化変異をきたしており、免疫チェックポイント阻害剤に不応性で極めて予後が悪い。申請者は、サルベージ経路でピリミジン塩基合成を促進する酵素が、LKB1不活化肺癌で高発現していることを新たに発見した。さらに、同因子をノックダウンすると、LKB1不活化肺癌細胞株の増殖が有意に抑制されることを見出し有望な治療標的になるという着想に至った。本研究では、LKB1不活化肺癌におけるピリミジン塩基のサルベージ経路が腫瘍増殖に果たす役割を解明すると同時に、同経路を標的とする新規治療法の開発を目指す。

 

Social Contribution 2

  1. 名古屋市公害健康被害認定審査会

    Role(s):Organizing member

    2025.4

  2. 愛知県公害健康被害認定審査会

    愛知県環境局環境政策課  2024.4 - 2025.3